Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect

Brain Research

Volumn 1426, Issue , 2011, Pages 1-17

  Padowski, Jeannie M ^a,b,c   Pollack, Gary M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Administration mode; Blood brain barrier; P glycoprotein; Tissue partitioning

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; PROTEIN;

ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD LEVEL; BRAIN METABOLISM; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROCESS MODEL; PROTEIN BINDING; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BODY FLUID COMPARTMENTS; BRAIN; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; METABOLIC CLEARANCE RATE; MICE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; TIME FACTORS; TISSUE DISTRIBUTION;

MUS;

EID: 81155131309     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.10.009     Document Type: Article

References (45)

1. T.L. Arens, and G.M. Pollack Nonstationary disposition of valproic acid during prolonged intravenous infusion: contributions of unbound clearance and protein binding Biopharm. Drug Dispos. 22 2001 243 249 (Pubitemid 34071873)
2. E. Beaulieu, M. Demeule, L. Ghitescu, and R. Beliveau P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain Biochem. J. 326 Pt 2 1997 539 544 (Pubitemid 27417234)
3. R. Bendayan, G. Lee, and M. Bendayan Functional expression and localization of P-glycoprotein at the blood brain barrier Microsc. Res. Tech. 57 2002 365 380 (Pubitemid 34579217)
4. H. Boxenbaum Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin J. Pharmacokinet. Biopharm. 8 1980 165 176 (Pubitemid 10003349)
5. P. Breedveld, J.H. Beijnen, and J.H. Schellens Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs Trends Pharmacol. Sci. 27 2006 17 24 (Pubitemid 43063120)
6. H.S. Chen, and J.F. Gross Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models J. Pharmacokinet. Biopharm. 7 1979 117 125 (Pubitemid 9148811)
7. D.E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration J. Pharm. Sci. 88 1999 815 821 (Pubitemid 29398551)
8. C. Dagenais, C. Rousselle, G.M. Pollack, and J.M. Scherrmann Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice J. Cereb. Blood Flow Metab. 20 2000 381 386 (Pubitemid 30108457)
9. C. Dagenais, J. Zong, J. Ducharme, and G.M. Pollack Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds Pharm. Res. 18 2001 957 963 (Pubitemid 32799940)
10. C. Dagenais, C.L. Graff, and G.M. Pollack Variable modulation of opioid brain uptake by P-glycoprotein in mice Biochem. Pharmacol. 67 2004 269 276 (Pubitemid 38112757)
11. A. Doran, R.S. Obach, B.J. Smith, N.A. Hosea, S. Becker, E. Callegari, C. Chen, X. Chen, E. Choo, J. Cianfrogna, L.M. Cox, J.P. Gibbs, M.A. Gibbs, H. Hatch, C.E. Hop, I.N. Kasman, J. Laperle, J. Liu, X. Liu, M. Logman, D. Maclin, F.M. Nedza, F. Nelson, E. Olson, S. Rahematpura, D. Raunig, S. Rogers, K. Schmidt, D.K. Spracklin, M. Szewc, M. Troutman, E. Tseng, M. Tu, J.W. Van Deusen, K. Venkatakrishnan, G. Walens, E.Q. Wang, D. Wong, A.S. Yasgar, and C. Zhang The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab. Dispos. 33 2005 165 174 (Pubitemid 40023528)
12. O. Fardel, V. Lecureur, P. Loyer, and A. Guillouzo Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells Biochem. Pharmacol. 49 1995 1255 1260
13. T.W. Gant, C.K. O'Connor, R. Corbitt, U. Thorgeirsson, and S.S. Thorgeirsson In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys Toxicol. Appl. Pharmacol. 133 1995 269 276
14. J.F. Ghersi-Egea, K.S. Monkkonen, C. Schmitt, J. Honnorat, M. Fevre-Montange, and N. Strazielle Blood-brain interfaces and cerebral drug bioavailability Rev. Neurol. (Paris) 165 2009 1029 1038
15. M. Gibaldi Effect of mode of administration on drug distribution in a two-compartment open system J. Pharm. Sci. 58 1969 327 331
16. P.L. Golden, and W.M. Pardridge Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain Cell. Mol. Neurobiol. 20 2000 165 181 (Pubitemid 30091454)
17. P.L. Golden, K.R. Brouwer, and G.M. Pollack Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis Pharm. Res. 10 1993 1765 1771 (Pubitemid 24000363)
18. M. Hammarlund-Udenaes, L.K. Paalzow, and E.C. de Lange Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method Pharm. Res. 14 1997 128 134 (Pubitemid 27146353)
19. E.J. Hammond, R.J. Perchalski, H.J. Villarreal, and B.J. Wilder In vivo uptake of valproic acid into brain Brain Res. 240 1982 195 198 (Pubitemid 12129293)
20. A.M. Hartz, and B. Bauer Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy Mol. Interv. 10 2010 293 304
21. H.E. Hassan, S.L. Mercer, C.W. Cunningham, A. Coop, and N.D. Eddington Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions Int. J. Pharm. 375 2009 48 54
22. J.C. Kalvass, and G.M. Pollack Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition Pharm. Res. 24 2007 265 276 (Pubitemid 46072186)
23. J.C. Kalvass, C.L. Graff, and G.M. Pollack Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice Pharm. Res. 21 2004 1867 1870 (Pubitemid 39390099)
24. J.C. Kalvass, T.S. Maurer, and G.M. Pollack Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios Drug Metab. Dispos. 35 2007 660 666 (Pubitemid 46513270)
25. J.C. Kalvass, E.R. Olson, M.P. Cassidy, D.E. Selley, and G.M. Pollack Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein- competent mice: assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data J. Pharmacol. Exp. Ther. 323 2007 346 355 (Pubitemid 47443282)
26. J.C. Kalvass, E.R. Olson, and G.M. Pollack Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-Glycoprotein efflux alters alfentanil brain disposition and antinociception Drug Metab. Dispos. 35 2007 455 459 (Pubitemid 46333909)
27. Lin, Y. Tai, M.T. Huang, Y.F. Tsai, H.J. Hsu, K.Y. Tzen, and H.H. Liou Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents J. Neurochem. 114 2010 717 727
28. X. Liu, B.J. Smith, C. Chen, E. Callegari, S.L. Becker, X. Chen, J. Cianfrogna, A.C. Doran, S.D. Doran, J.P. Gibbs, N. Hosea, J. Liu, F.R. Nelson, M.A. Szewc, and J. Van Deusen Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding J. Pharmacol. Exp. Ther. 313 2005 1254 1262 (Pubitemid 40727030)
29. C. Marzolini, E. Paus, T. Buclin, and R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin. Pharmacol. Ther. 75 2004 13 33 (Pubitemid 38130115)
30. D.S. Miller Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier Trends Pharmacol. Sci. 31 2010 246 254
31. M. Miyajima, H. Kusuhara, M. Fujishima, Y. Adachi, and Y. Sugiyama Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice Drug Metab. Dispos. 39 2011 814 819
32. J.M. Padowski A Multi-factorial Approach to Understanding and Predicting Brain Exposure to Pharmacologic Agents 2008 University of North Carolina at Chapel Hill Chapel Hill, NC
33. J.M. Padowski, and G.M. Pollack Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation Methods Mol. Biol. 596 2010 359 384
34. G.M. Pollack, and K.L. Brouwer Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat J. Pharmacokinet. Biopharm. 19 1991 189 225
35. T.J. Raub P-glycoprotein recognition of substrates and circumvention through rational drug design Mol. Pharm. 3 2006 3 25 (Pubitemid 43331747)
36. K.D. Read, and S. Braggio Assessing brain free fraction in early drug discovery Expert Opin. Drug Metab. Toxicol. 6 2010 337 344
37. A. Reichel Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept Chem. Biodivers. 6 2009 2030 2049
38. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, C.A. Mol, M.A. van der Valk, E.C. Robanus-Maandag, and H.P. te Riele Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 1994 491 502 (Pubitemid 24153990)
39. A.H. Schinkel, U. Mayer, E. Wagenaar, C.A. Mol, L. van Deemter, J.J. Smit, M.A. van der Valk, A.C. Voordouw, H. Spits, O. van Tellingen, J.M. Zijlmans, W.E. Fibbe, and P. Borst Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc. Natl. Acad. Sci. U. S. A. 94 1997 4028 4033 (Pubitemid 27180493)
40. F.J. Sharom Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1) Biochem. Cell Biol. 84 2006 979 992 (Pubitemid 46450697)
41. S.G. Summerfield, K. Read, D.J. Begley, T. Obradovic, I.J. Hidalgo, S. Coggon, A.V. Lewis, R.A. Porter, and P. Jeffrey Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction J. Pharmacol. Exp. Ther. 322 2007 205 213 (Pubitemid 46956363)
42. S.J. Thompson, K. Koszdin, and C.M. Bernards Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein Anesthesiology 92 2000 1392 1399 (Pubitemid 30257201)
43. J. Westerhout, M. Danhof, and E.C. De Lange Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting J. Pharm. Sci. 100 2011 3577 3593
44. R. Zhao, J.C. Kalvass, S.B. Yanni, A.S. Bridges, and G.M. Pollack Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration Drug Metab. Dispos. 37 2009 529 535
45. S.F. Zhou, L.L. Wang, Y.M. Di, C.C. Xue, W. Duan, C.G. Li, and Y. Li Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development Curr. Med. Chem. 15 2008 1981 2039